Rimonabant - Acomplia Effectively Reduces Visceral Fat in the Obese Patient as Confirmed by Abdominal Computer Tomography Scan 

It seems to have two entirely diferent but useful effets. One is that it helps you to stop smoking (a very good idea in itself). The other is that at the same time it also reduces appetite. It appears to do both by not working on the body itself, at all, but by playing tricks with the brain’s regulation of your appetitite.The full press release: Accomplea is the first of a class of medicines that blocks the so-called endocannabinoid system in the central nervous system thereby enabling to control appetite as well as the urge to smoke. People who tend to eat more often have an over-stimulated endocannabinoid system. Acomplia blocks some receptors in the endocannabinoid system, giving it improved balance, which in turn curbs appetite and the urge to overeat.

PARIS, Sept. 19, 2007-The first direct evidence of the effects of Acomplia® (purchase rimonabant) in significantly reducing human visceral fat (the metabolically active fat wrapped around the body’s vital organs in the abdomen, such as liver, pancreas) is being presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD).

The visceral fat area was significantly more reduced with rimonabant 20mg (-40.6cm2) than with placebo (-20.3cm2); (p< 0.0001).Visceral fat is a cardio-metabolic risk factor in Japanese patients as it is in the global studies. Visceral fat accumulation has been shown to correlate with a number of other cardio-metabolic risk factors, such as dyslipidemia, insulin resistance, hyperinsulinaemia, glucose intolerance and type 2 diabetes.

526 obese Japanese patients (BMI equal or greater than 25 kg/m2) with associated cardio-metabolic risk factors from 73 centres were exposed for this double-blind, placebo-controlled parallel-group 6-month study duration, to determine the effective dose of rimonabant (5, 10 and 20mg) on body weight and multiple cardiometabolic risk factors. The inclusion criteria included at least 2 of the following cardiometobolic risk factors: impaired glucose tolerance, type 2 diabetes, dyslipidemia (hypertriglyceridemia and/or low HDLcholesterolemia) or hypertension.

The primary endpoint was reduction in body weight. Important secondary endpoints included percentage of patients responders on body weight, waist circumference, visceral fat area (VFA) assessed by CT scan, HDLcholesterol, and triglycerides. Rimonabant 20 mg demonstrated significant improvement on all these endpoints from baseline to six months compared to the placebo arm.

Rimonabant 20mg demonstrated a favorable safety profile with a discontinuation rate from treatment due to adverse events higher with placebo (7.6%) versus rimonabant 20 mg (4.5%). Overall more than 86 percent of the patients completed treatment.

The rimonabant 20mg dose is being studied in 3 ongoing phase III clinical trials in Japan.

About intra-abdominal fat Obesity is traditionally determined by an indirect measure, the BMI (get cheap rimonabant online,body mass index). The BMI does not take into account type and distribution of adipose tissue. Two types of adipose tissue exist in the human body, characterised by anatomical and metabolic differences:

Subcutaneous fat, located directly under the skin contains small insulin-sensitive adipocytes (fat cells,low cost rimonabant-acomplia), while the visceral fat (inter-abdominal adipose tissue), wrapped around the organs in the abdomen, contains large insulinresistant adipocytes.

The visceral fat is the metabolically more active fat. Excess visceral fat, present in patients with abdominal obesity, leads to metabolic imbalance, such as lipid disorders, insulin resistance and type 2 diabetes, factors leading to cardio-metabolic disease. Waist circumference is used in daily practice to determine the presence of abdominal obesity. To directly quantify the visceral fat one applies an imaging technique, the computer tomography. This method was integrated in the trial presented today, to study the direct effect of rimonabant on this dangerous body fat.

About Rimonabant
Acomplia® (rimonabant) is approved in 42 countries. In the European Union, Acomplia® (rimonabant) is approved for the treatment of obese patients (order generic acomplia onlineBMI equal to or greater than 30kg/m2), or those overweight (BMI greater than 27 kg/m2) with associated risk factors such as Type 2 diabetes or dyslipidemia, in conjunction with diet and physical exercise (see section 5.1).

In pivotal clinical trials lasting up to two years, rimonabant significantly reduced body weight and waist
circumference, a measure of intra-abdominal fat. Rimonabant also improved blood glucose levels, HDL, triglycerides (order cheap acomplia,fats in the blood), and insulin sensitivity.

The most common adverse events associated with rimonabant were consistent across studies and included gastrointestinal (nausea, vomiting, diarrhea), nervous system (headache, dizziness, paresthesia/
hypoesthesia/dysesthesia) and psychiatric disorders (order rimonabant,anxiety, insomnia, depressed mood and depression).

About sanofi-aventis
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such
products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update
or revise any forward-looking information or statements.
 

Purchase acomplia lowest price - The Miracle Pill
What is obesity? Obesity is a state when you take in more calories than the calories burnt. It affects your body metabolism and results in the dissolution of fat in your body.Purchase acomplia Obesity comes with many other health-related problems like irregular blood pressure, pain in joints, and many more.It is for sure that losing weight is not an easy task. It is the demand of recent times to lose excess body weight at the earliest.Purchase acomplia, Everyone strives hard not just to wipe out their excess body weight, but also to stay healthy Though exercise is the best remedy for dissolving extra fat of your body, it is seen that only few of us are able to avail the benefits of exercise. It can be due to many reasons like inability to exercise, laziness, medical condition, and hectic schedules. Subsequently, diet pills therapy comes in to action by providing an easier method to shelve excess body weight. Acomplia diet pill is like a boon for those people who don’t want to spend most of their time in exercises.

Acomplia diet pill is an innovative way to remove extra pounds from your body. Acomplia work effectively by suppressing your appetite. You can lose your excess weight when you take these diet pills in combination with mild exercises and a balanced diet.

A weight-loss drug used by thousands of UK patients should not be taken by people on anti-depressants, a European health watchdog warned yesterday delivery overnight in guaranteed acomplia stock.

The European Medicines Agency (EMEA) said it was recommending that anyone taking anti-depressants or suffering ongoing major depression should not take rimonabant, which is sold under the brand name Acomplia.

About 41,000 patients in the UK have been treated with rimonabant since it was launched here in June 2006 lowest price for acomplia.

A new exercise pill turns your body into a fat-burning machine allowing it to burn twice the fat.The pill has been developed by American scientists and to this point stil does not have a name. The pill is in early stages of development but could cure the obesity crisis in America as well as the world.The pill has been tested i mice thus far. The pill allowed the mice to eat a very high-fat diet without gaining an ounce. This would be a major break-through as it would allow more freedom in the diets of fast-paced peopel around the world.The pill works by triggering the same type of fat-burning processes which occur when you go to the gym or go for a run. This exercise can be doubled by taking the pill. When they are not active, the mice continued to burn fat.

Dr. Ronald Evans stated “Too few people get an ideal amount of exercise. Having access to an exercise pill would improve the quality of muscles, and increase the burning of energy or excess fat [lowering] the risks of heart disease and diabetes.”The rule of thumb is as long as more calories are burned than taken in, you will lose weight.

Have you ever heard of a miracle drug which can be applied both as weight loss diet pills as well as a medicine for smoking surcease?

Yes, there is a miracle drug which can be applied for both the intents. The name of the medicine is Acompila and whose generic name is rimonabant.

Acomplia diet pills are anorectic anti fleshiness drug which should be applied for an obese someone with physical structure the great unwasheds index of 30 or more.

In acute causas when a someone is suffering from Type 2 diabetes or any other physical structure problems, this oral medicine may be urged for obese someone with Physical structure Masses Index of 27 or more.

Sanofi the manufacturer of Acomplia Diet Pills has printed some Acomplia Info which we are discussing below.(buy acomplia)

Checkup name of Acompila is Rimonabant which is a CB 1 cannabinoid receptor opposer.

The drug is available in Acomplia Pharmaceutics UK where the medicine was first acquainted after receiving approving from the European Trades union.

Later the drug was acquainted in Denmark and later distributed gradually in other European states.

However, the medicine is yet to have approving from the Nutrient and Drug Disposal in the USA for which the medicine is not yet available in the CesaOnline.com.

It is heard that if the medicine is acquainted in the CesaOnline.com marketplace after receiving approving from the FDA, the trade name of the medicine will be Zimulti.

European Trades union has given approving to the medicine to be acquainted in the marketplace on the recommendation that the medicine should be applied along with diet and physical exertion for decrease of physical structure weight. Acomplia Diet Pills are prescription drug and before employment a doc must be confer withed.(Purchase Acomplia)

Another miraculous result of Acomplia diet pills is smoking surcease. It is bumped that employment of Acomplia diet pills trim downs the involvement in smoking. This issues to the patients in quitting smoking.

The Cheap Acomplia diet pills are constructed by Sanofi, which should be bought only through Prescription from an experienced doc.

The medicine has been bumped to be effective for weight loss as well as effective against certain metabolic upsets and tie ined cardiovascular peril factors. But if you want to employment the medicine for cosmetic physical structure weight decrease, the medicine may not be much effective. Rather it will create other problems link uped to its side issues.

Also European Trades union has o.k.ed its approving only for physical structure weight decrease intent.

As I stated earlier that the medicine is effective for smoking surcease. But the approving for this has yet been obtained neither from EU nor from FDA.

However, off the label of the medicine can be applied for this intent. A doc should be confer withed before employment for other intent also.

So why do you waffle? Confer with your doc if your physical structure the great unwasheds index is 30 or more and / or you are suffering from weight link uped diseases. Spell to purchase Acomplia if your doc urges and start your weight loss programme with diet and physical exertion and with this miracle medicine. Diminution of craving to smoking will be a bonus for you.
 

Rimonabant (Acomplia - Rimonabant) Successful Again in Reducing Weight, Waist European study says it also reduced factors for heart disease in obese people

April 15, 2005 - Acomplia - Rimonabant. which is still going by its generic name rimonabant, while it awaits FDA approval, has again won accolades for reducing bodyweight, waist circumference, and risk factors for heart disease in obese people, according to results of a randomized trial published in this week’s issue of The Lancet.

Luc Van Gaal (University Hospital Antwerp, Belgium) and colleagues undertook a trial (RIOEurope,buy acomplia) involving 1507 obese people from Europe and the USA.

Participants had a body mass index (BMI) of 30 kg/m 2or greater, or a BMI greater than 27 kg/m2with abnormal blood fat levels, high blood pressure, or both. They were randomly assigned 5mg or 20mg of a drug called rimonabant, or a placebo once daily in addition to a calorie controlled diet. The treatment groups had similar characteristics. 920 patients (61%) completed the one-year follow-up; 379 in the rimonabant 5mg group, 363 in the rimonabant 20mg group and 178 in the placebo group.(Buy Cheap Acomplia)

Weight loss at 1 year was greater in patients treated with 5 mg or 20 mg of rimonabant compared with placebo. More than 67% of patients who completed treatment with 20mg of rimonabant achieved 5% or more weight loss, and 39% achieved 10 % or more weight loss. Patients on 20 mg of rimonabant had greater improvements than placebo in waist circumference (average reduction of 4 cm), and cardiovascular risk factors including cholesterol, insulin resistance and prevalence of metabolic syndrome. The pattern of weight loss seen with rimonabant was sustained for around 36-40 weeks.

The most common side effects leading to study discontinuation were depressed mood disorders in all treatment groups; withdrawals due to nausea, vomiting, diarrhea, headache, dizziness, and anxiety were more frequent in the rimonabant 20 mg group than in other groups. Serious adverse events did not occur more frequently in patients treated with the drug than in those on placebo.

Professor Van Gaal concludes: “In this study, treatment with rimonabant over 1 year led to sustained, clinically meaningful weight loss, reduction in waist circumference, and associated improvements in several cardiovascular and metabolic risk factors.”

In an accompanying Comment Uberto Pagotto and Renato Pasquali (Buy Discount Acomplia on Sant Orsola-Malpighi General Hospital, Bologna, Italy) state: “These data, and those from the other ongoing clinical trials with rimonabant, might presumably help us to better tackle obesity and related metabolic and cardiovascular disease. When additional drugs are available, we will also have the possibility to individually target the therapeutic strategies according to phenotype characteristics and to the pathophysiological mechanism